Engel and colleagues [26] examined the impact of apolipoprotein E (APOE) polymorphisms on cognitive function in CIS/RRMS patients, revealing that APOE4 homozygosity was linked to a reduced overall cognitive performance (p = 0.020). Here, APOE is linked to in situ carcinoma.